The use of other percutaneous LAA closure devices, including but not limited to the LARIAT, PLAATO, and AMPLATZER devices, for stroke prevention in individuals with atrial fibrillation is considered experimental/investigational because the safety and/or effectiveness of these devices cannot be established by the available published peer-reviewed literature.
Note: *CHADS2 score: Congestive heart failure, hypertension, age greater than 75, diabetes, stroke/transient ischemia attack/thromboembolism.
Note: ** CHA2DS2-VASc score: Congestive heart failure, hypertension, age greater than or equal to 65, diabetes, stroke/transient ischemia attack/thromboembolism, vascular disease, sex category.
Note: NVAF is defined as a rhythm disturbance that occurs in the absence of rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve or mitral valve repair.
CHADS2 and CHADS2-VASc Scores to Predict Ischemic Stroke Risk in Individuals with Atrial Fibrillation
Risk Scheme
|
Low Risk
|
Intermediate Risk
|
High Risk
|
CHADS2
(2001) classic
|
Score 0
|
Score 1-2
|
Score 3-6
|
CHADS2—revised
|
Score 0
|
Score 1
|
Score 2-6
|
The 2009 Birmingham Schema Expressed as a Point-Based Scoring System, With the Acronym CHA2DS2-VASc
Risk Factor
|
Score
|
Congestive heart failure/LV dysfunction
|
1
|
Hypertension
|
1
|
Age ≥ 75 y
|
2
|
Diabetes mellitus
|
1
|
Stroke/TIA/TE
|
2
|
Vascular disease (prior myocardial infarction, peripheral artery disease, or aortic plaque)
|
1
|
Age 65-74 y
|
1
|
Sex category of female (female sex confers higher risk)
|
1
|